Trial Now Recruiting: A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease (NCT06826612)

WHY IT MATTERS

This is one of the first human trials of SPK-10001, a gene therapy specifically designed to target the genetic cause of Huntington's disease, offering hope for a disease that currently has no cure.

Researchers are testing a new gene therapy called SPK-10001 to treat Huntington's disease, a rare brain disorder that causes movement problems and cognitive decline. This early-stage study will check if the treatment is safe and whether it helps patients. About 53 people with Huntington's disease will participate in this trial, which is being run by Roche, a major pharmaceutical company.

NCT ID: NCT06826612 Status: RECRUITING Conditions: Huntington Disease Phase: PHASE1, PHASE2 Enrollment: 53 Sponsor: Hoffmann-La Roche Summary: The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.

YOU CAN ACT ON THIS

If you have Huntington's disease or a family member does, check the full trial details at clinicaltrials.gov (NCT06826612) to see if you meet eligibility requirements and contact the study team about enrollment.